Kerendia

Finerenone, the active ingredient in Kerendia, is a mineralocorticoid receptor antagonist presented as a tablet for oral use. It is employed to treat chronic kidney disease associated with type 2 diabetes and hypertension in adult patients.

GNH USA supplies Kerendia as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to stringent quality standards and providing the product to hospitals, pharmacies and clinics worldwide. The company ensures reliable logistics, regulatory compliance, and supports pharmacovigilance for safe patient use. With a focus on timely delivery and product integrity, GNH USA meets the needs of global healthcare providers.

Kerendia (finerenone) is indicated for renal and cardiovascular conditions where mineralocorticoid receptor activation contributes to disease progression.

- Chronic kidney disease associated with type 2 diabetes: slows decline of kidney function and reduces albuminuria. - Hypertension: assists in blood pressure reduction as part of a comprehensive antihypertensive regimen.

Finerenone may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hyperkalemia: elevated serum potassium levels. - Hypotension: low blood pressure, especially when standing. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hyperkalemia: potentially life‑threatening potassium elevation. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue or airway.

When prescribing finerenone, clinicians should observe several precautionary measures to minimize risk.

- Monitor serum potassium: check potassium levels before initiation and periodically during therapy. - Assess renal function: evaluate eGFR at baseline and follow‑up visits. - Adjust dose in moderate hepatic impairment: consider reduced dosing or increased monitoring. - Avoid use in patients with existing hyperkalemia: contraindicated if potassium >5.0 mmol/L. - Pregnancy and breastfeeding: safety not established; use only if potential benefit justifies risk. - Store at below 25°C: keep tablets in the original container, protect from moisture and light.

Finerenone can interact with other medicines, influencing potassium balance or its metabolism.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): may cause dangerous hyperkalemia. - ACE inhibitors or ARBs: combined use can increase serum potassium and affect renal function. - Potassium supplements: additive risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may raise finerenone plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce finerenone effectiveness. - NSAIDs: can impair renal function and exacerbate potassium retention.